Search results for: Breast
#33631531 2021/02/13 To Up
Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: Significance in drug release, uptake, and cytotoxicity in breast cancer cells.Nanoparticle-based drug delivery systems, in combination with high-affinity disease-specific targeting ligands, provide a sophisticated landscape in cancer theranostics. Due to their high diversity and specificity to target cells, antibodies are extensively used to provide bioactivity to a plethora of nanoparticulate systems. However, controlled and reproducible assembly of nanoparticles (NPs) with these targeting ligands remains a challenge. In this context, determinants such as ligand density and orientation, play a significant role in antibody bioactivity; nevertheless, these factors are complicated to control in traditional bulk labeling methods. Here, we propose a microfluidic-assisted methodology using a polydimethylsiloxane (PDMS) Y-shaped microreactor for the covalent conjugation of Trastuzumab (TZB), a recombinant antibody targeting HER2 (human epidermal growth factor receptor 2), to doxorubicin-loaded PLGA/Chitosan NPs (PLGA/DOX/Ch NPs) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysulfosuccinimide (sNHS) mediated bioconjugation reactions. Our labeling approach led to smaller and less disperse nanoparticle-antibody conjugates providing differential performance when compared to bulk-labeled NPs in terms of drug release kinetics (fitted and analyzed with DDSolver), cell uptake/labeling, and cytotoxic activity on HER2 + breast cancer cells in vitro. By controlling NP-antibody interactions in a laminar regime, we managed to optimize NP labeling with antibodies resulting in ordered coronas with optimal orientation and density for bioactivity, providing a cheap and reproducible, one-step method for labeling NPs with globular targeting moieties.
Noé Escareño, Natalia Hassan, Marcelo J Kogan, Josué Juárez, Antonio Topete, Adrián Daneri-Navarro
1038 related Products with: Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: Significance in drug release, uptake, and cytotoxicity in breast cancer cells.
#33631497 2021/02/09 To Up
Convolutional neural networks for breast cancer detection in mammography: A survey.Despite its proven record as a breast cancer screening tool, mammography remains labor-intensive and has recognized limitations, including low sensitivity in women with dense breast tissue. In the last ten years, Neural Network advances have been applied to mammography to help radiologists increase their efficiency and accuracy. This survey aims to present, in an organized and structured manner, the current knowledge base of convolutional neural networks (CNNs) in mammography. The survey first discusses traditional Computer Assisted Detection (CAD) and more recently developed CNN-based models for computer vision in mammography. It then presents and discusses the literature on available mammography training datasets. The survey then presents and discusses current literature on CNNs for four distinct mammography tasks: (1) breast density classification, (2) breast asymmetry detection and classification, (3) calcification detection and classification, and (4) mass detection and classification, including presenting and comparing the reported quantitative results for each task and the pros and cons of the different CNN-based approaches. Then, it offers real-world applications of CNN CAD algorithms by discussing current Food and Drug Administration (FDA) approved models. Finally, this survey highlights the potential opportunities for future work in this field. The material presented and discussed in this survey could serve as a road map for developing CNN-based solutions to improve mammographic detection of breast cancer further.
Leila Abdelrahman, Manal Al Ghamdi, Fernando Collado-Mesa, Mohamed Abdel-Mottaleb
2645 related Products with: Convolutional neural networks for breast cancer detection in mammography: A survey.
#33631478 2021/02/09 To Up
An update on the role of long non-coding RNAs in the pathogenesis of breast cancer.Breast cancer is the most frequent female malignancy. This malignancy has diverse clinical and molecular subtypes with different prognoses. Dysregulation of long non-coding RNAs (lncRNAs) not only participates in the development of breast cancer, but also affects the clinical course and prognosis of this type of cancer. Hundreds of studies have shown up-regulation or down-regulation of lncRNAs in breast cancer samples or serum samples of affected individuals suggesting these RNA molecules as diagnostic markers for breast cancer. Different anticancer agents such as trastuzumab, lapatinib, doxorubicin, hydroxyurea, docetaxel, 5-fluorouracil and 6-thioguanine affect expression profile of lncRNAs. In the present article, we review the results of investigations about the role of lncRNAs in the evolution of breast cancer.
Soudeh Ghafouri-Fard, Kasra Honarmand Tamizkar, Bashdar Mahmud Hussen, Mohammad Taheri
1427 related Products with: An update on the role of long non-coding RNAs in the pathogenesis of breast cancer.
Error loading info... Pleas try again later.
#33631392 2021/02/22 To Up
[Covid-19 and breast cancer: first lessons of a pandemic].
Carole Mathelin, Massimo Lodi100ul100ul
No related Items
#33631331 2021/02/22 To Up
Clinical and Genetic factors associated with the Breast cancer-related Sleep Disorders: The "CAGE-Sleep" study- a cross-sectional study.Despite being among the most reported concerns in breast cancer patients, sleep disturbances are still poorly assessed and managed in routine clinical practice. Correctly evaluating these symptoms and understanding the underlying clinical and genetic factors would help medical teams develop an adequate treatment strategy for each patient.
Aline Hajj, Roula Hachem, Rita Khoury, Tamara Nehme, Souheil Hallit, Fady Nasr, Fady El Karak, Georges Chahine, Joseph Kattan, Lydia Rabbaa Khabbaz
1942 related Products with: Clinical and Genetic factors associated with the Breast cancer-related Sleep Disorders: The "CAGE-Sleep" study- a cross-sectional study.
#33631321 2021/02/22 To Up
Guideline No. 416: Labour, Delivery, and Postpartum Care for People with Physical Disabilities: (En français : Soins pendant l'accouchement et la période post-partum chez les personnes ayant un handicap physique).To describe evidence-based practice for managing the labour, delivery, and postpartum care of people with physical disabilities in Canada.
Anne Berndl, Noor Ladhani, R Douglas Wilson, Melanie Basso, Elizabeth Jung, Lesley A Tarasoff, Pamela Angle, Nancy Soliman
1998 related Products with: Guideline No. 416: Labour, Delivery, and Postpartum Care for People with Physical Disabilities: (En français : Soins pendant l'accouchement et la période post-partum chez les personnes ayant un handicap physique).1 x 961 mg 500 ml 1,000 tests500 Units100 units4 x 10,000 Units 100100 Units100ug100
No related Items
#33631225 2021/02/22 To Up
Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade.The combination of MAPK-targeted therapy and immune checkpoint blockade is one of the most promising regimens for patients with advanced melanoma. However, the synergistic efficacy of the combo regimen is still controversial in clinical trials. Here, we report that MAPK inhibition induced T-cell suppression within tumor microenvironment is mediated by attenuation of HSP27/HSP70 and deficiency of neoantigen presentation. To address this problem, we designed a photothermal-responsive on-demand controlled drug release gold nano-system to carry BRAF inhibitor. The nano-system can be specifically delivered into tumor cells rather than T-cells, and effectively transformed the optical energy into heat energy upon laser irradiation. Combination of photothermal and targeted therapy significantly promoted immunogenic cell death and T-cell infiltration. On top of this regimen, systematically administration of PD-1 antibody not only suppressed local-treated tumor but also inhibited abscopal tumor by enhancing generalized immune-related antitumor response. More importantly, the triple-combo regimen could efficiently convert immune "cold" tumors into "hot" ones. In conclusion, our research proves the advantage of photothermal-targeted-immune triple combinatorial regimen in treating tumors which are clinical unresectable multifocal and lack of T-cell infiltration.
Xiaowei Liu, Yanlin Feng, Jie Xu, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang, Hubing Shi
2012 related Products with: Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade.100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized100ug0.1ml (1mg/ml)100 μg100ug100ug Lyophilized
#33631041 2021/02/25 To Up
Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study.The number of patients with atrial fibrillation (AF) and cancer is rapidly increasing in clinical practice. The impact of cancer on clinical outcomes in this patient population is unclear, as is the performance of the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) and CHA DS -VASc (Congestive Heart Failure, Hypertension, Age ≥ 75 years, Diabetes Mellitus, Stroke or Transient Ischemic Attack, Vascular Disease, Age 65 to 74 Years, Sex Category) scores.
Daniele Pastori, Amélie Marang, Arnaud Bisson, Danilo Menichelli, Julien Herbert, Gregory Y H Lip, Laurent Fauchier
2345 related Products with: Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study.
#33630696 2021/02/25 To Up
Reduction mammoplasty and mastopexy in the previously irradiated breast - a systematic review and meta-analysis.Breast cancer is the most common cancer diagnosed in women, and early stages are treated with lumpectomy and irradiation. Irradiation, however, leads to reduced vascularization and fibrosis, which may influence the cosmetic outcome unfavourably and increase complications after subsequent surgery on irradiated breasts. Patients with significant asymmetry after treatment may desire corrective reduction mammoplasty or mastopexy, but this may be associated with increased complication rates. This systematic review and meta-analysis aimed to investigate postoperative complication rates after bilateral reduction mammoplasty or mastopexy in women who had undergone unilateral lumpectomy and irradiation. PubMed, Medline, EMBASE and Cochrane databases were searched for eligible studies. After screening titles and abstracts, 14 full text studies were reviewed, and 7 of these were included in the analysis. The meta-analysis showed a significantly higher complication rate in the irradiated breast compared to the non-irradiated breast, rate ratio 4.82 (95% CI: 1.58, 14.70), = 0.006. The complication rate was 54% in the irradiated breast (58/107) compared to 8% (9/107) in the non-irradiated breast ( = 0.034). This study suggests that reduction mammoplasty or mastopexy in the previously irradiated breast is associated with a significantly increased risk of complications. Careful patient selection and information are paramount in the treatment of this patient group.
Anne Kathrine Lorentzen, Jørgen Lock-Andersen, Louise Wichmann Matthiessen, Tobias Wirenfeldt Klausen, Lisbet Rosenkrantz Hölmich
1211 related Products with: Reduction mammoplasty and mastopexy in the previously irradiated breast - a systematic review and meta-analysis.500 mg100ul25 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia